Challenges remain in current cervical cancer screening approaches that can now be addressed with more advanced technologies.
The molecular and biomarker-based tests in the Roche Cervical Cancer Portfolio bring greater diagnostic certainty to cervical cancer screening to guide clinicians and women along each step, removing ambiguity that can arise in current testing approaches.
SCREEN
with the cobas® HPV test
The cobas® HPV test is FDA-approved for all cervical screening indications: ASC-US reflex, co-testing, and primary screening to assess the risk for cervical precancer and cancer. cobas HPV simultaneously provides pooled results on known high-risk HPV genotypes, and individual results on the two highest-risk genotypes, HPV 16 and HPV 18, giving three results in one from a single sample.
TRIAGE
with CINtec® PLUS Cytology
CINtec® PLUS Cytology is the only FDA-approved triage test that uses dual-biomarker technology to simultaneously detect p16 and Ki-67 in women with HPV-positive results. The co-expression of these two biomarkers is a strong indicator that an HPV infection is undergoing oncogenic transformation.
DIAGNOSE
with CINtec® Histology
CINtec® Histology enhances identification of occult cervical lesions that may be missed by H&E or morphologic interpretation alone. The CINtec® Histology test is the only clinically validated test that uses advanced p16 biomarker technology to confirm the presence or absence of cervical lesions due to transforming HPV infections.
References
